RT Journal Article SR Electronic T1 Atypical B cells and impaired SARS-CoV-2 neutralisation following booster vaccination in the elderly JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.10.13.22281024 DO 10.1101/2022.10.13.22281024 A1 Isabella A.T.M. Ferreira A1 Colin Y.C. Lee A1 William Foster A1 Adam Abdullahi A1 Zewen Kelvin Tuong A1 Benjamin J Stewart A1 John R. Ferdinand A1 Stephane Guillaume A1 Martin O.P. Potts A1 Marianne Perera A1 Benjamin A. Krishna A1 Ana P. Alonso A1 Mia Cabantous A1 Steven A. Kemp A1 Lourdes Ceron-Gutierrez A1 Soraya Ebrahimi A1 The CITIID-NIHR BioResource COVID-19 Collaboration A1 Paul Lyons A1 Kenneth GC Smith A1 John Bradley A1 Dami A. Collier A1 Sarah A. Teichmann A1 Laura E. McCoy A1 Paul A. MacAry A1 Rainer Doffinger A1 Mark R. Wills A1 Michelle Linterman A1 Menna R. Clatworthy A1 Ravindra K. Gupta YR 2022 UL http://medrxiv.org/content/early/2022/10/13/2022.10.13.22281024.abstract AB Age is a major risk factor for hospitalization and death after SARS-CoV-2 infection, even in vaccinees. Suboptimal responses to a primary vaccination course have been reported in the elderly, but there is little information regarding the impact of age on responses to booster third doses. Here we show that individuals 70 or older who received a primary two dose schedule with AZD1222 and booster third dose with mRNA vaccine achieved significantly lower neutralizing antibody responses against SARS-CoV-2 spike pseudotyped virus compared to those younger than 70. One month after the booster neither the concentration of serum binding anti spike IgG antibody, nor the frequency of spike-specific B cells showed differences by age grouping. However, the impaired neutralization potency and breadth post-third dose in the elderly was associated with enrichment of circulating “atypical” spike-specific B cells expressing CD11c and FCRL5. Single cell RNA sequencing confirmed an expansion of TBX21-, ITGAX-expressing B cells in the elderly that enriched for B cell activation/receptor signalling pathway genes. Importantly we also observed impaired T cell responses to SARS-CoV-2 spike peptides in the elderly post-booster, both in terms of IFNgamma and IL2 secretion, as well as a decrease in T cell receptor signalling pathway genes. This expansion of atypical B cells and impaired T cell responses may contribute to the generation of less affinity-matured antibodies, with lower neutralizing capacity post-third dose in the elderly. Altogether, our data reveal the extent and potential mechanistic underpinning of the impaired vaccine responses present in the elderly after a booster dose, contributing to their increased susceptibility to COVID-19 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe Wellcome Trust Addenbrookes Charitable Trust BRCAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the East of England Cambridge Central Research Ethics Committee (17/EE/0025). PBMC from unexposed volunteers previously recruited by the NIHR BioResource Centre Cambridge through the ARIA study (2014-2016), with ethical approval from the Cambridge Human Biology Research Ethics Committee (HBREC.2014.07) and currently North of Scotland Research Ethics Committee 1 (NS/17/0110). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors